Welcome to our dedicated page for NUGENE INTERNATIONAL news (Ticker: NUGN), a resource for investors and traders seeking the latest updates and insights on NUGENE INTERNATIONAL stock.
NuGene International, Inc. (symbol: NUGN), based in Irvine, California, is a dynamic leader in the skincare and hair care industries in the United States. The company develops and markets a wide range of personalized skincare products, including universal cream, serums for eyes and facial use, gel, and face wash products. In addition to skincare, NuGene offers an array of hair care products such as regenerative shampoos and conditioners, and specialized anti-hair loss serums. NuGene is also engaged in pioneering research and the formulation of a topical burn cream designed for effective burn treatment.
The company caters to multiple segments including wholesale distributors, physicians, and direct consumers, showcasing its ability to penetrate diverse market channels. NuGene International has shown an unwavering commitment to cutting-edge biotechnology, bringing innovative solutions from its laboratory to the consumer's shelf.
Recently, NuGene International, Inc. reported significant achievements that underline its growth trajectory. These include the approval of its Form 10 by the Securities and Exchange Commission (SEC), marking a key milestone towards becoming a fully reporting public entity with aspirations to list on major exchanges like NASDAQ. This approval signifies the company’s dedication to transparency and regulatory compliance while providing prospective investors with comprehensive data to inform their investment decisions.
Financially robust, NuGene boasts a portfolio exceeding $46 million in total assets. The company has made notable strides in expanding its footprint across Europe and Africa, demonstrating its global reach and influence. Additionally, the company's subsidiary, BOXO Productions, has been instrumental in driving revenue growth through successful movie and TV projects.
NuGene International continues to innovate and develop, investing in advancements in robotics and AI, further enhancing its competitive edge. This diversified approach, coupled with strategic acquisitions and partnerships, positions NuGene as a formidable player in the industry.
NuGene International, Inc./Livento Group (OTC Pink: NUGN) announced the release of the film "Savage Salvation" in select cinemas and on streaming platforms, starting December 2, 2022. Starring notable actors like Robert De Niro and John Malkovich, the film marks a significant entry for BOXO Productions. The company anticipates a substantial revenue increase in Q4 2022 and Q1 2023 due to box office and streaming sales. BOXO has funded 5-7 films in 2022 and plans 12-15 more films in 2023, potentially generating up to $75 million in revenue for upcoming productions.
NuGene International, Inc./Livento Group, Inc. (OTC Pink: NUGN) is exploring an acquisition of a Software Engineering Company specializing in AI and Robotics, with due diligence ongoing. This company has reported a 50% year-over-year growth and aims to enter new markets. Livento CEO David Stybr emphasized the sustainable revenue and positive EBITDA of the target company, which has eight engineers delivering services in Europe. The acquisition aims to bolster Livento's Elisee program and expand market opportunities in the US. Further details will follow post-due diligence.
NuGene International, Inc./Livento Group Inc. (OTC Pink: NUGN) announced its subsidiary, BOXO Productions, has initiated two new film projects, increasing its total to five within eight months. One project is an adaptation of a children's best-seller, projected to earn over USD 70 million at the box office by early 2025. The second is a futuristic thriller aimed at a global audience, anticipating box office sales exceeding USD 100 million. CEO David Stybr estimates potential box office revenues from these projects between USD 180-300 million in the next two years.
NuGene International, Inc. (OTC Pink: NUGN) reported its Q3 2022 results, highlighting total assets of $24.4 million and a revenue increase of $515,120, marking over 30% growth year-to-date. Adjusted EBITDA stood at $114,149. The company enhanced its content library and increased marketing visibility. Despite some administrative costs amounting to $400,971, the balance sheet remains debt-free, supporting future growth. Looking ahead, substantial revenue and EBITDA increases are anticipated in Q4 2022.
NuGene International, Inc. (OTC Pink: NUGN) has announced significant progress on its Euro Dot project, which aims to establish a holding company through a reverse merger with a European entity. This initiative focuses on eco-friendly logistics solutions, targeting a combined company value of USD 70 million. The merger is expected to complete in October, with further acquisitions planned within 6-12 months, potentially increasing Livento Group's stake from 15% to a larger share. Livento Group specializes in disruptive business models, including film production.
NuGene International, Inc. (OTC Pink: NUGN) has successfully completed its Rezidence Geminos project in Prague, selling all 16 condominium units, with total gross sales expected to reach $8 million.
Acquired in 2019, the project underwent updates to meet market demands and was financed with UniCredit bank. The modern building offers energy-efficient designs, parking, and proximity to public transport.
Livento Group's CEO, David Štýbr, highlighted the project's significance for investor value and the company's focus shift to its BOXO and Elisee divisions.
NuGene International, Inc./Livento Group (OTC Pink: NUGN) announced CEO David Štýbr's presentation at the Proactive One2One Virtual Forum. Livento focuses on acquiring established businesses with growth potential, seeking to complete two upcoming IPOs, including one linked to NuGene. The company has successfully completed several real estate projects and acquired BOXO Productions, a prominent film production company. Livento aims to expand operations into logistics with Euro Dot, targeting over $40 million in combined revenues from initial companies, enhancing shareholder value.
NuGene International, Inc. (OTC Pink: NUGN) announced its participation in the Proactive One2One Investor Forum on August 9, 2022. CEO David Štýbr will present at 2 p.m. EDT, highlighting the company’s disruptive business model. The presentation will be accessible via Proactive’s website and YouTube after the event. Štýbr aims to discuss EURO DOT, BOXO Productions, and future acquisition targets. Livento Group focuses on high-growth investments, with Elisee, an AI tool designed to optimize portfolios.
NuGene International, Inc./Livento Group LLC (OTC Pink: NUGN) announced an interview with CEO David Štýbr, discussing their disruptive business model and three primary sectors: AI, real estate, and film production through BOXO Productions. The company is shifting focus from real estate, hindered by low material supply due to inflation, to capitalize on the lucrative film industry. Livento's proprietary AI software aids portfolio management and is currently tested by a significant German fund. The company aims for up-listing on major exchanges and forecasts BOXO as a future revenue driver.
NuGene International, Inc./Livento Group LLC (OTC Pink: NUGN) reported significant growth in 2021 as it aims for a higher trading exchange. The company is expanding into film and television, developing its AI program, and completing real estate projects. Key events for Q4 2022 include the film "Wash Me In A River" set for September release, a planned IPO of logistics company Euro Dot expected to enhance revenue, and a name change to Livento Group, anticipated by August. The company is also seeking to upgrade to OTCQB status.
FAQ
What is the current stock price of NUGENE INTERNATIONAL (NUGN)?
What is the market cap of NUGENE INTERNATIONAL (NUGN)?
What does NuGene International, Inc. specialize in?
Where is NuGene International, Inc. located?
What are some of the products offered by NuGene International?
Who are the primary customers of NuGene International?
What recent achievements has NuGene International, Inc. reported?
What are some key financial metrics for NuGene International, Inc.?
What are NuGene International’s recent market expansions?
What is BOXO Productions?
Is NuGene International involved in any emerging technologies?
How can I find more information about NuGene International and its subsidiaries?
